Medscape9h
HFpEF and Obesity: Breakthrough Results With GLP-1 Therapies
A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!
Yes, GLP-1 Medications Really Do Reduce Alcohol Cravings, Per A New Study
It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...
Veru Inc.: Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...
Medscape1d
GLP-1 Reduces Recurrent Ischemic Stroke in Type 2 Diabetes
Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...
Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch
Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...
Psychology Today12d
New Weight Loss Medications May Help Treat Addiction
New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...
Monthly Prescribing Reference14d
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
The numbers of patients diagnosed with thyroid cancer were 0.17% in the GLP-1 RA group, 0.23% in the DPP4i group, 0.17% in the SGLT2i group, and 0.20% in the sulfonylurea group. (HealthDay News ...